Shuttle Pharmaceuticals (SHPH) said late Tuesday it has priced its public offering of up to about 3 million shares and warrants to purchase an additional 3 million shares at a combined price of $1.525 per share and accompanying warrant.
Gross proceeds from the offering are estimated to be about $4.5 million.
The warrants will have an exercise price of $1.40 per share, are immediately exercisable and expire five years after issuance.
Proceeds from the offering, which are expected to close around Thursday, will be used to fund trials of its product candidates, including $2.3 million owed to Theradex Systems for support in phase 2 trials of radiation sensitizer Ropidoxuridine, as well as for general corporate purposes.
Price: 1.7300, Change: -0.07, Percent Change: -3.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。